{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:05:16Z","timestamp":1790719516878,"version":"4.1.0"},"reference-count":71,"publisher":"Informa UK Limited","issue":"7","funder":[{"name":"Rib-X Pharmaceuticals Inc"},{"DOI":"10.13039\/100016956","name":"Melinta Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016956","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.2217\/fmb.15.39","type":"journal-article","created":{"date-parts":[[2015,6,29]],"date-time":"2015-06-29T09:40:52Z","timestamp":1435570852000},"page":"1111-1123","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":74,"title":["Delafloxacin, A Non-Zwitterionic Fluoroquinolone in Phase III of Clinical Development: Evaluation of its Pharmacology, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy"],"prefix":"10.1080","volume":"10","author":[{"given":"Fran\u00e7oise","family":"Van Bambeke","sequence":"first","affiliation":[{"name":"Pharmacologie cellulaire et mol\u00e9culaire, Louvain Drug Research Institute, Universit\u00e9 catholique de Louvain, Avenue E Mounier 73 B1.73.05, 1200Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,6,29]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1586\/eri.13.12"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2013.45.1.22"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit020"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2014.00551"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e328332e672"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2011.02.005"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2013.86"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-664-1_16"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.4161\/viru.22507"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2014.935470"},{"issue":"3","key":"e_1_3_4_13_1","first-page":"123","article-title":"Quinolones: recent structural and clinical developments","volume":"4","author":"Emami S","year":"2005","unstructured":"Emami S , ShafieeA , ForounmadiA . Quinolones: recent structural and clinical developments . Ir. J. Pharm. Res.4 ( 3 ), 123 \u2013 136 ( 2005 ).","journal-title":"Ir. J. Pharm. Res."},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2005.01131.x"},{"key":"e_1_3_4_15_1","unstructured":"Yazaki A NiinoY OhshitaYet al. WO1996JP02710 19960920(US5998436) ( 1999 )."},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.9.3008-3011.2003"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.6.1867-1874.2003"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh180"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.6.1875-1881.2003"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3260-3269.2003"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh304"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.12.3973-3975.2003"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg363"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.2.283-286.2000"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.7.2771-2777.2004"},{"key":"e_1_3_4_26_1","volume-title":"50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","author":"Duffy E","year":"2010","unstructured":"Duffy E , DevitoJA , RemyJ , BurakE . Delafloxacin chemical properties lead to increased potency against Gram-positive pathogens, including quinolone-resistant pathogens II . Preseneted at : 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) . MA, USA , 12\u201315 September 2010 ( Abstract E183 )."},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01201-10"},{"key":"e_1_3_4_28_1","volume-title":"50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","author":"Burak E","year":"2010","unstructured":"Burak E , DevitoJA , RemyJ , DuffyE . Delafloxacin chemical properties lead to increased potency against Gram-positive pathogens, including quinolone-resistant pathogens I . Presented at : 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) . MA, USA , 12\u201315 September 2010 ( Abstract E182 )."},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.01.094"},{"issue":"3","key":"e_1_3_4_30_1","first-page":"377","article-title":"DNA gyrase, topoisomerase IV, and the 4-quinolones","volume":"61","author":"Drlica K","year":"1997","unstructured":"Drlica K , ZhaoX . DNA gyrase, topoisomerase IV, and the 4-quinolones . Microbiol. Mol. Biol. Rev.61 ( 3 ), 377 \u2013 392 ( 1997 ).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1089\/107662903765826697"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-11-241"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.2.354"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00672-10"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.1.187"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg224"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.082092899"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1347"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks307"},{"key":"e_1_3_4_40_1","first-page":"C-1399","volume-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Kurz SG","year":"2014","unstructured":"Kurz SG , DuffyE , BalthazarJ , BomonoRA , ShaferWM . Delafloxacin exerts potent anti-gonococcal activity despite mutations that decrease antibiotic susceptibility due to target modification or drug efflux . Presented at : 54th Interscience Conference on Antimicrobial Agents and Chemotherapy . DC, USA , C-1399 ( 2014 )."},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1086\/511642"},{"key":"e_1_3_4_42_1","volume-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Remy J","year":"2014","unstructured":"Remy J , MarraA , DuffyE . Evaluation of the potential for delafloxacin resistance development in Neisseria gonorrhoeae . Presented at : 54th Interscience Conference on Antimicrobial Agents and Chemotherapy . DC, USA , 6\u20139 September 2014 ( Abstract C-1412a )."},{"key":"e_1_3_4_43_1","volume-title":"21st European Congress of Clinical Microbiology and Infectious Diseases & 27th International Congress of Chemotherapy","author":"Lawrence L","year":"2011","unstructured":"Lawrence L , PillarC , SahmD , BurakE . In vitro activity of delafloxacin against European isolates of Staphylococcus aureus from skin and soft tissue, respiratory, urine and blood specimens . Presented at : 21st European Congress of Clinical Microbiology and Infectious Diseases & 27th International Congress of Chemotherapy . Milan, Italy , 7\u201310 May 2011 ( Abstract P-1185 )."},{"key":"e_1_3_4_44_1","volume-title":"52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","author":"Lawrence L","year":"2012","unstructured":"Lawrence L , HopkinsS , SahmDet al. Characterization and In vitro Activity of delafloxacin (DLX) against isolates from a phase 2 study of acute bacterial skin and skin structure infections (ABSSSI) . Presented at : 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) . CA, USA , 9\u201312 September 2012 ( Abstract E-208 )."},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/JB.186.24.8407-8423.2004"},{"key":"e_1_3_4_46_1","volume-title":"51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","author":"Lawrence L","year":"2011","unstructured":"Lawrence L , BenedictM , HartJet al. Pharmacokinetics (PK) and safety of single doses of delafloxacin administered intravenously in healthy human subjets . Presented at : 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) . IL, USA , 17\u201320 September 2011 ( A2\u2013045a )."},{"key":"e_1_3_4_47_1","volume-title":"52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","author":"Lawrence L","year":"2012","unstructured":"Lawrence L , LongcorJ , LiDet al. Metabolism and mass balance of [14C]-Delafloxacin in healthy human volunteers following intravenous administration . 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) . CA, USA , 9\u201312 September 2012 ( Abstract A1956 )."},{"key":"e_1_3_4_48_1","volume-title":"50th Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Rubino CM","year":"2010","unstructured":"Rubino CM , BhavnaniSM , BurakE , AmbrosePG . Pharmacokinetic-pharmacodynamic target attainment analyses supporting delafloxacin phase 3 dose regimen decisions . Poster presented at : 50th Interscience Conference on Antimicrobial Agents and Chemotherapy . MA, USA , 12\u201315 September 2010 ( Poster A1\u2013681 )."},{"key":"e_1_3_4_49_1","volume-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Hoover R","year":"2014","unstructured":"Hoover R , LawrenceL , BenedictMet al. Pharmacokinetics and relative bioavailability of intravenous and oral formulations of delafloxacin (DLX) in healthy subjects . Presented at : 54th Interscience Conference on Antimicrobial Agents and Chemotherapy . DC, USA , 5\u20139 September 2014 ( Abstract A-682 )."},{"key":"e_1_3_4_50_1","volume-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Hoover R","year":"2014","unstructured":"Hoover R , LawrenceL , BenedictMet al. Pharmacokinetics of a 900 mg oral formulation of delafloxacin (DLX) healthy subjects supporting a gonorrhea phase 3 study . Presented at : 54th Interscience Conference on Antimicrobial Agents and Chemotherapy . DC, USA , 5\u20139 September 2014 ( Abstract A-056a )."},{"key":"e_1_3_4_51_1","volume-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Hoover R","year":"2014","unstructured":"Hoover R , LawrenceL , BenedictMet al. A phase 1, open-label, crossover study to determine the effect of food on the pharmacokinetics of a single dose of oral delafloxacin (DLX) in healthy subjects . Presented at : 54th Interscience Conference on Antimicrobial Agents and Chemotherapy . DC, USA , 5\u20139 September 2014 ( Abstract A-683 )."},{"key":"e_1_3_4_52_1","volume-title":"52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","author":"Hoover R","year":"2012","unstructured":"Hoover R , LawrenceL , LongcorJ , GreenfieldJ . Pharmacokinetics (PK) of pelafloxacin (DLX), vancomycin (VAN), and linezolid (LNZ) in a phase 2 exploratory study in subjects with acute bacterial skin and skin structure infections (ABSSSI) . Presented at : 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) . CA, USA , 9\u201312 September 2012 ( Abstract A1957 )."},{"key":"e_1_3_4_53_1","volume-title":"53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","author":"Hoover R","year":"2013","unstructured":"Hoover R , LawrenceL , SmithC , LongcorJ . Pharmacokinetics (PK) of delafloxacin (DLX) in patients with varying degrees of renal impairment . Presented at : 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) . CO, USA , 10\u201313 September 2013 ( Abstract A-017E )."},{"key":"e_1_3_4_54_1","volume-title":"21st European Congress of Clinical Microbiology and Infectious Diseases & 27th International Congress of Chemotherapy","author":"Ding Y","year":"2011","unstructured":"Ding Y , VilletMA , LeeJC , HooperDC . Treatment of renal abscesses caused by Staphylococcus aureus MW2, using delafloxacin and moxifloxacin . Presented at : 21st European Congress of Clinical Microbiology and Infectious Diseases & 27th International Congress of Chemotherapy . Milan, Italy , 10 May 2011 ( Poster P1506 )."},{"key":"e_1_3_4_55_1","volume-title":"50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","author":"Marra A","year":"2010","unstructured":"Marra A , BortolonE , MolstadDet al. Evaluation of delafloxacin in rat granuloma pouch infections caused by Gram-negative pathogens . Presented at : 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) . MA, USA , 12\u201315 September 2010 ( Abstract A1\u2013680 )."},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.5.669"},{"key":"e_1_3_4_57_1","volume-title":"49th Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Burak E","year":"2009","unstructured":"Burak E , BortolonE , MolstadDet al. Pharmacokinetics and pharmacodynamics of delafloxacin in S. aureus murine thigh infection models . 49th Interscience Conference on Antimicrobial Agents and Chemotherapy . CA, USA , 12\u201315 September 2009 ( Abstract A1\u20131941 )."},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh242"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.02.004"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.02.026"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2008.11.005"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.4161\/viru.2.5.17724"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg223"},{"issue":"3","key":"e_1_3_4_64_1","first-page":"249","article-title":"Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic\/pharmacodynamic model of uninfected and infected macrophages","volume":"38","author":"Vallet CM","year":"2011","unstructured":"Vallet CM , MarquezB , NgabiranoEet al. Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic\/pharmacodynamic model of uninfected and infected macrophages . Int. J. Antimicrob. Agents38 ( 3 ), 249 \u2013 256 ( 2011 ).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00181-13"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03482-14"},{"key":"e_1_3_4_67_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijid.2014.10.009","article-title":"A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections","volume":"30","author":"O\u2019Riordan W","year":"2014","unstructured":"O\u2019Riordan W , MehraP , ManosPet al. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections . Int. J. Infect. Dis.30C , 67 \u2013 73 ( 2014 ).","journal-title":"Int. J. Infect. Dis."},{"key":"e_1_3_4_68_1","volume-title":"52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","author":"Longcor J","year":"2012","unstructured":"Longcor J , LawrenceL , DuffyE , HopkinsS . Objective measures of clinical efficacy in a Phase 2B Exploratory Study of delafloxacin (DLX) compared to vancomycin (VAN) and linezolid (LNZ) in adults with acute bacterial skin and skin structure infections (ABSSSI) . Presented at : 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) . CA, USA , 9\u201312 September 2012 ( Abstract L1\u20131667c )."},{"key":"e_1_3_4_69_1","volume-title":"52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","author":"Longcor J","year":"2012","unstructured":"Longcor J , HopkinsS , LawrenceLet al. Results of a phase 2 study of delafloxacin (DLX) compared to vancomycin (VAN) and linezolid (LNZ) in acute bacterial skin and skin structure infections (ABSSSI) . Presented at : 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) . CA, USA , September 2012 ( Abstract L1\u20131663 9\u201312 )."},{"key":"e_1_3_4_70_1","volume-title":"52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","author":"Longcor J","year":"2012","unstructured":"Longcor J , HopkinsS , LawrenceLet al. Results of a phase 2 study of delafloxacin (DLX) compared with vancomycin (VAN) and linezolid (LNZ) in acute bacterial skin and skin structure infections (ABSSSI) . Presented at : 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) . CA, USA , 9\u201312 September 2012 ( Abstract L1\u20131663 )."},{"key":"e_1_3_4_71_1","volume-title":"52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","author":"Lawrence L","year":"2012","unstructured":"Lawrence L , BenedictM , LitwinJet al. A thorough Phase 1 QTc study of delafloxacin (DLX) compared with placebo and moxifloxacin (MXF) . Presented at : 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) . CA, USA , 9\u201312 September 2012 ( Abstract A1958 )."},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X253735"},{"key":"e_1_3_4_73_1","volume-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Soge OO","year":"2014","unstructured":"Soge OO , RobertsMC , LendermanCet al. Evaluation of In vitro activity of delafloxacin against contemporary neisseria gonorrhoeae isolates . Presented at : 54th Interscience Conference on Antimicrobial Agents and Chemotherapy . DC, USA , 5\u20139 September 2014 ( Abstract C-1401 )."}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb.15.39","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:38:45Z","timestamp":1719124725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb.15.39"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,29]]},"references-count":71,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.2217\/fmb.15.39"],"URL":"https:\/\/doi.org\/10.2217\/fmb.15.39","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-06-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}